TSE treatments were performed on three horses without general anaesthesia at the Royal Veterinary College in London
Scandinavian ChemoTech’s Animal Care division, Vetiqure, has successfully conducted training of staff at Royal Veterinary College (RVC) Equine, who afterwards performed three very promising TSE (Tumour Specific Electroporation) treatments without general anaesthesia.
The three horses treated were suffering from melanomas and sarcoids situated in various locations. All horses could successfully be treated under sedation in combination with local anaesthesia and/or nerve block, which has not been possible before with their older static electroporation device.
The fact that general anaesthesia could be fully avoided is a great breakthrough taking into consideration the safety of the horse, the time spent on the entire procedure but also the cost reduction it entails for the clinic and ultimately for the owners of the animals.
“This marks a very positive start to the 6-month clinical evaluation period of the vetIQure™ and TSE technology and we look forward to continuously monitoring the clinical outcomes.” – says Mohan Frick, CEO
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
